PUBLISHER: The Business Research Company | PRODUCT CODE: 1760702
PUBLISHER: The Business Research Company | PRODUCT CODE: 1760702
Propranolol is a non-selective beta-blocker that reduces heart rate, blood pressure, cardiac workload, anxiety, and helps in migraine prevention. It works by blocking the effects of adrenaline on the heart and blood vessels, thereby lowering heart rate and blood pressure. Propranolol is also commonly prescribed to manage symptoms of anxiety, particularly performance anxiety.
The main forms of propranolol dosage include tablets, injectable solutions, extended-release capsules, and oral solutions. Propranolol tablets are solid oral medications containing propranolol hydrochloride, designed for rapid absorption to treat conditions such as high blood pressure, arrhythmias, and anxiety. They are typically taken multiple times a day with flexible dosing. Propranolol is used for a variety of indications, including hypertension, angina pectoris, migraine prevention, post-traumatic stress disorder (PTSD), essential tremors, and therapeutic options for anxiety disorders. It is employed by a range of end-users, including hospitals, clinics, home healthcare settings, nursing homes, and pharmaceutical companies.
The propranolol drug market research report is one of a series of new reports from The Business Research Company that provides propranolol drug market statistics, including the propranolol drug industry global market size, regional shares, competitors with the propranolol drug market share, detailed propranolol drug market segments, market trends, and opportunities, and any further data you may need to thrive in the propranolol drug industry. This propranolol drug market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenarios of the industry.
The propranolol drug market size has grown strongly in recent years. It will grow from $1.05 billion in 2024 to $1.11 billion in 2025 at a compound annual growth rate (CAGR) of 5.8%. The growth during the historic period can be attributed to factors such as the rising incidence of migraine disorders, an increasing focus on affordable healthcare solutions, growing adoption of beta-blockers in post-surgery recovery, expanding healthcare infrastructure in developing regions, and a rising demand for long-acting drug formulations.
The propranolol drug market size is expected to see strong growth in the next few years. It will grow to $1.37 billion in 2029 at a compound annual growth rate (CAGR) of 5.5%. The growth during the forecast period can be attributed to factors such as the growing demand for non-invasive treatments, increasing research and development in cardiovascular drugs, rising healthcare spending in emerging economies, and the increasing adoption of personalized medicine in cardiovascular treatments. Key trends in the forecast period include advancements in sustained-release formulations, the development of advanced drug delivery systems, innovations in personalized medicine for cardiovascular treatments, the integration of digital health tools with drug therapy, and advanced research in combination therapies for anxiety and hypertension.
The rising prevalence of cardiovascular diseases (CVDs) is expected to drive the expansion of the propranolol drug market. CVDs are a group of disorders affecting the heart and blood vessels, including conditions such as coronary artery disease, heart failure, and stroke. The increase in cardiovascular diseases is largely due to unhealthy eating habits, with excessive consumption of processed foods and fats leading to elevated cholesterol levels, which in turn raise the risk of heart-related issues. Propranolol is effective in managing these diseases by regulating heart rate and lowering blood pressure, making it particularly beneficial for patients with hypertension and arrhythmias. The drug also enhances heart function, reducing the risk of heart attacks and strokes, thus improving overall cardiovascular health. For example, in May 2024, the Centers for Disease Control and Prevention (CDC) reported that heart disease caused 702,880 deaths in 2022, accounting for one in every five deaths in the U.S. Additionally, around 805,000 people in the United States suffer a heart attack each year. Consequently, the growing prevalence of cardiovascular diseases is driving the demand for propranolol.
Key players in the propranolol drug market are focusing on developing advanced formulations, such as extended-release propranolol drugs, to improve patient adherence and overall therapeutic outcomes. Extended-release formulations are designed to gradually release the drug over time, ensuring sustained therapeutic effects and reducing the need for frequent dosing. This not only improves patient compliance but also enhances treatment effectiveness. For example, in August 2023, Lupin Pharma Canada Ltd., a pharmaceutical company based in Canada, launched long-acting propranolol capsules in response to the discontinuation of Inderal long-acting (LA). The new extended-release formulation, available in doses of 60 mg, 80 mg, 120 mg, and 160 mg, offers consistent symptom relief for Canadian patients, improving adherence and treatment outcomes, while increasing healthcare access.
In December 2024, Exicure Inc., a biotechnology company based in the U.S., entered into a partnership with GPCR Therapeutics Inc. This collaboration aims to bolster Exicure's position as a clinical-stage biotech company by acquiring technical expertise and gaining access to GPCR Therapeutics' proprietary CXCR4 inhibitor technology. This partnership enhances Exicure's drug development pipeline, particularly in the areas of immuno-oncology, fibrosis, and obesity treatments. GPCR Therapeutics Inc., based in South Korea, is also involved in the manufacturing of propranolol drugs.
Major players in the propranolol drug market are Pfizer Inc., Teva Pharmaceutical Industries Ltd., Boehringer Ingelheim International GmbH, Sandoz Group AG, Fresenius Kabi AG, Cipla Limited, Hikma Pharmaceuticals PLC, Amneal Pharmaceuticals Inc., Lupin Limited, Alkem Laboratories Ltd., Torrent Pharmaceuticals Ltd., Ipca Laboratories Limited, Mankind Pharma Ltd., Lannett Company Inc., Jubilant Pharma Holdings Inc., Actiza Pharmaceutical Private Limited, Mylan Laboratories Inc., Neurocon Inc., Neuracle Lifesciences Pvt. Ltd., Yabang Pharmaceutical Group Co. Ltd.
North America was the largest region in the propranolol drug market in 2024. The regions covered in propranolol drug report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.
The countries covered in the propranolol drug market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.
The propranolol drug market consists of sales of intravenous (IV) infusion. Values in this market are 'factory gate' values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.
The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).
The revenues for a specified geography are consumption values and are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.
Propranolol Drug Global Market Report 2025 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.
This report focuses on propranolol drug market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.
Where is the largest and fastest growing market for propranolol drug ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? The propranolol drug market global report from the Business Research Company answers all these questions and many more.
The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.
The forecasts are made after considering the major factors currently impacting the market. These include the Russia-Ukraine war, rising inflation, higher interest rates, and the legacy of the COVID-19 pandemic.